Literature DB >> 21982499

7-(4H-1,2,4-Triazol-3-yl)benzo[c][2,6]naphthyridines: a novel class of Pim kinase inhibitors with potent cell antiproliferative activity.

Fabrice Pierre1, Eric Stefan, Anne-Sophie Nédellec, Marie-Claire Chevrel, Collin F Regan, Adam Siddiqui-Jain, Diwata Macalino, Nicole Streiner, Denis Drygin, Mustapha Haddach, Sean E O'Brien, Kenna Anderes, David M Ryckman.   

Abstract

A novel class of pan-Pim kinase inhibitors was designed by modifying the CK2 inhibitor CX-4945. Introduction of a triazole or secondary amide functionality on the C-7 position and 2'-halogenoanilines on C-5 resulted in potent inhibitors of the Pim-1 and Pim-2 isoforms, with many analogs active at single digit nanomolar concentrations. The molecules inhibited the phosphorylation at Serine 112 of the apoptosis effector BAD, and had potent antiproliferative effects on the AML cell line MV-4-11 (IC(50) <30 nM). This work delivers an excellent lead-optimization platform for Pim targeting anticancer therapies.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21982499     DOI: 10.1016/j.bmcl.2011.09.059

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  12 in total

1.  Characterization of HJ-PI01 as a novel Pim-2 inhibitor that induces apoptosis and autophagic cell death in triple-negative human breast cancer.

Authors:  Yu-Qian Zhao; Yi-Qiong Yin; Jie Liu; Gui-Hua Wang; Jian Huang; Ling-Juan Zhu; Jin-Hui Wang
Journal:  Acta Pharmacol Sin       Date:  2016-07-11       Impact factor: 6.150

2.  Identification of novel inhibitors for Pim-1 kinase using pharmacophore modeling based on a novel method for selecting pharmacophore generation subsets.

Authors:  Rand Shahin; Lubna Swellmeen; Omar Shaheen; Nour Aboalhaija; Maha Habash
Journal:  J Comput Aided Mol Des       Date:  2015-12-19       Impact factor: 3.686

Review 3.  PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer.

Authors:  Sutapa Mahata; Pranab K Sahoo; Ranita Pal; Sinjini Sarkar; Tanuma Mistry; Sushmita Ghosh; Vilas D Nasare
Journal:  Med Oncol       Date:  2022-05-15       Impact factor: 3.064

4.  Discovery and identification of PIM-1 kinase inhibitors through a hybrid screening approach.

Authors:  Mingfeng Shao; Yiming Yuan; Kun Yu; Kai Lei; Guonian Zhu; Lijuan Chen; Mingli Xiang
Journal:  Mol Divers       Date:  2014-02-12       Impact factor: 2.943

5.  Proposed Allosteric Inhibitors Bind to the ATP Site of CK2α.

Authors:  Paul Brear; Darby Ball; Katherine Stott; Sheena D'Arcy; Marko Hyvönen
Journal:  J Med Chem       Date:  2020-10-29       Impact factor: 7.446

Review 6.  Protein kinase CK2: a potential therapeutic target for diverse human diseases.

Authors:  Christian Borgo; Claudio D'Amore; Stefania Sarno; Mauro Salvi; Maria Ruzzene
Journal:  Signal Transduct Target Ther       Date:  2021-05-17

7.  Computational prediction and experimental validation of a novel synthesized pan-PIM inhibitor PI003 and its apoptosis-inducing mechanisms in cervical cancer.

Authors:  Zhongyu Liu; Weihua He; Jianglin Gao; Junhua Luo; Xian Huang; Chunfang Gao
Journal:  Oncotarget       Date:  2015-04-10

8.  Structural analysis of PIM1 kinase complexes with ATP-competitive inhibitors.

Authors:  Jozefina Bogusz; Karol Zrubek; Krzysztof P Rembacz; Przemyslaw Grudnik; Przemyslaw Golik; Malgorzata Romanowska; Benedykt Wladyka; Grzegorz Dubin
Journal:  Sci Rep       Date:  2017-10-17       Impact factor: 4.379

9.  Synthesis of new pyridothienopyrimidinone and pyridothienotriazolopyrimidine derivatives as pim-1 inhibitors.

Authors:  Hala B El-Nassan; Bassem H Naguib; Engy A Beshay
Journal:  J Enzyme Inhib Med Chem       Date:  2018-12       Impact factor: 5.051

10.  Pharmacophore modeling and in silico toxicity assessment of potential anticancer agents from African medicinal plants.

Authors:  Fidele Ntie-Kang; Conrad Veranso Simoben; Berin Karaman; Valery Fuh Ngwa; Philip Neville Judson; Wolfgang Sippl; Luc Meva'a Mbaze
Journal:  Drug Des Devel Ther       Date:  2016-07-04       Impact factor: 4.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.